Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AMERICAN REGENT, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1967-01-01

Employees: 501

Market Cap: -

Website: http://www.americanregent.com

Clinical Trials

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

Phase 1

Completed

Conditions: Methemoglobinemia
Congenital Methemoglobinemia

Interventions: Drug: Methylene Blue

First Posted Date: 2015-06-23

Last Posted Date: 2025-06-05

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 12

Registration Number: NCT02478281

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Phase 3

Completed

Conditions: Cancer and Chemotherapy Related Anemia

Interventions: Other: Normal Saline
Drug: Injectafer

First Posted Date: 2015-05-25

Last Posted Date: 2021-05-11

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 244

Registration Number: NCT02453334

Locations: 🇺🇸
Compassionate Care Research Group, Inc., Riverside, California, United States
🇺🇸
University Cancer Institute, Boynton Beach, Florida, United States
🇺🇸
AR Development Solutions, Miami Lakes, Florida, United States

and more 24 locations

A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

Phase 2

Completed

Conditions: Iron Deficiency Anemia (IDA)

Interventions: Drug: Ferric Carboxymaltose (FCM)

First Posted Date: 2015-04-07

Last Posted Date: 2022-07-25

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 35

Registration Number: NCT02410213

Locations: 🇵🇱
Szpital Uniwersytecki Katedra i Klinika Pediatrii, Hematologii i Onkologii, Bydgoszcz, Poland
🇵🇱
Zespół Opieki Zdrowotnej w Dębicy z siedzibą w Dębicy , Oddział Dziecięcy, Dębica, Poland
🇵🇱
Uniwersytecki Szpital Dziecięcy w Krakowie, Oddział Pediatrii i Gastroenterologii (V), Kraków, Poland

and more 7 locations

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Phase 2

Completed

Conditions: Iron Deficiency
Fibromyalgia

Interventions: Drug: Placebo
Drug: Injectafer

First Posted Date: 2015-04-06

Last Posted Date: 2018-02-20

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 81

Registration Number: NCT02409459

Locations: 🇺🇸
Clinical Research Solutions, Franklin, Tennessee, United States

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

Phase 3

Completed

Conditions: Restless Legs Syndrome (RLS)

Interventions: Other: Placebo
Drug: Injectafer

First Posted Date: 2015-03-24

Last Posted Date: 2021-10-12

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 209

Registration Number: NCT02397057

Locations: 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Synergy San Diego, National City, California, United States
🇺🇸
Desert Valley Research, Rancho Mirage, California, United States

and more 16 locations

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

Phase 4

Completed

Conditions: Iron Deficiency Anemia Secondary to IBD or Gastric Bypass

Interventions: Drug: Ferrous Sulfate tablets
Drug: Injectafer

First Posted Date: 2014-03-13

Last Posted Date: 2020-09-17

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 198

Registration Number: NCT02086968

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

Completed

Conditions: Iron Deficiency Anemia (IDA)

First Posted Date: 2013-11-14

Last Posted Date: 2018-01-24

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 551

Registration Number: NCT01984554

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Phase 4

Completed

Conditions: Iron Deficiency Anemia (IDA)

Interventions: Drug: SOC
Drug: Injectafer

First Posted Date: 2013-09-25

Last Posted Date: 2025-05-22

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 1025

Registration Number: NCT01950247

Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures

Phase 3

Completed

Conditions: Pain

Interventions: Drug: SPRIX

First Posted Date: 2013-03-27

Last Posted Date: 2015-07-07

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 60

Registration Number: NCT01819610

Locations: 🇺🇸
Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Phase 2

Completed

Conditions: Restless Legs Syndrome (RLS)

Interventions: Drug: Ferric Carboxymaltose (FCM)
Drug: Placebo

First Posted Date: 2011-06-27

Last Posted Date: 2018-02-20

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 45

Registration Number: NCT01382901

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy